ࡱ> `!LX75;ky D=Ƽ"BQzxxY |e?}dly˚6a aI)!ZSIl$&K6PyFKJIA\|ݛI|s\:׹u׭ȏyOQ0-s\@@57\STDh;r3Lw>{ uˢl݌vk䰜(s9cG>u`t]mW.7FpX_8U|2"{d7LQZZJߕ۟%1ҢEoAO6#nF ˞$k<]+f}3p='{dRʎ^CWi9옵qkZTeDwүSˡʹ"Q9*=J۲5}dtP_:<c!Ύ5~_L8qqv&syWٽ׎JGo^wzpY/(ݽa_|Uͪ:~׈?pGjʹcxD,-g$gݚ_+A;`SMUDUEVb@=19fLCrGOk;윸8Gl2=,SoBe)Y$Yy$%$yŃإ .I" tR"POI^ePA^hDA<,D (2f}**fhؑ,_0Q),j,VP0Ua-XS eyD!̍: ^.eVoLXk Z3ZVb~`M))/.XUJ[[Y9. }y{%׮烊iQ/dSodEUYCqfi,ae&U9h04Gyt<$<䇝)sn'\Yu [+Q33|B<5(hͧ@96>K %I9y/_\Ae@S6 =.5xR\SP5\nqzcЎEmkJ-B{ 2`r $5'u{j߫vpG<>6lU/%Xb~].ĜKa5٨vov G=(.S|Xej T y՟ PoGvdr@n丝C N8>Z-DZyWڷ=箊G$ؔ/]//ﳦ=ڟfڰ͙Xs<2c= dY!Pu@{9WBo5O5XGK "_^لHo "A~:'{J5+5+ȌbdI{~i ћBUx^\d\ {/`/|3O?=9@3̰9:-܄;qO5= zw,E 4 KG*ЁnƉ dBmF!F9ל_핯kTZZjK%Eb 5ԌAo(}{+:#̀d͹3h*m'LR=ħ.P:u! ^8f$SCwĘ? 'R},_=o:7x4^eGۣ\"胺}jzݾ=rOU-|&Jsy{tuґĒyh¨TsGsg&b]wZ?ʤc?P;}?A{]; թMO=(OwYhi4[wWt[*fnJ@閴S׺ tL'9N`[=&3NqfGjgSٖ:O1{Rs0 u0s(̥f>sw,f1ƼO f 6vS{s/R78aS'[%URaeS᪖3)sU.Tu:5u@ y3)j~ xHzڪ ڢ o>M6] LWR}1ꃴ@=h dI34 "%t>LQz@Q. ljgR+= ?ȥ8=?O5?hA͏ 3 77۲0OS$v"ʼLѦvSf_!OCVF~H顈G;NTtDv 2 224M;=u4ݍL[8CHҽ:'!kC'#u8NK8=ӓ׍z4 :&`d@M.zV#+j$\zXo‰ЛY b"-L !B-_yT ߷;We:uNaˀ2@!88q 40_W1 Ǿh4/yBG%<|+u̯%68"($3bsRy}FrI,)^rB 'AO asq;*F 0?ErJe-Ywty^&8PH2u$`i]żl_͍|\\aN16!`(;—~C: @(|v߁~6 wbm|I[qpsDq" vhO ~_IL{f/s{4Ixގwp޴2/"M N[bз%qR"K |̝d3n=[:]e߉W\?NKxo|IоŅ8,`j|aC[!< t1~Jny3C,%FJS]$Qz4أ"h/H-{q&^&U?]6[K ?w{0fo1|:?Hfe#}s'E>mX]AiHo/;0fތ:J};z>ЋBZoxG쵃xOԇ$~%b6]ā6_$>7Acv.2t @{Q jH4CSԡhԤƨ Q"QvշFƃ&@#:UG=">ioO*\ۮ䅊u@YQlYk6ZQj::1hoF;HGR(lYBQGk Ӳ{XD!惈:VV6*,n6a35UHOٛ$yҹ'nnMr['qf6 g?@B/9*Mkƿ B\?o_>n)6WpX`! {ĠЧx`Qxb xW tVySTS7 DD#KBEDRe ! RD֖" .sO's7s̝ǔ@s&X ɫՒw7v~\SJ!(T9^K>Kt\ 9[Z=Ƭa?bY# sF >:)|Լ1.ǰg䵴}&"0T\(9&IF%%#ڳ܌J=y>ev*I ez֜#A}>FMxb|~.oc_8ӓ`-y] )CS~5=.-ⶴYҁ)%1Xsp,>szx$w ˾p'\hvWJުW6dB˯uAڃꥼR3xK?W\ɏ#n|!f du<\o:sn1 $|{&t{@/Vj9s>Zf];u%yߴ2>a͟#?u saNPoP{/ͻv'T`"MohzX[=w\)@2ca%eiDCVS7=A=}cEƑZ;rgڊ[h"&.*oG"i>*&`x9X\Ͼop \3ig|Mb=4,zݯwڟ梽HڅT-TϢ4$a~tΤKG;J@\ ,EM+h|-ᐹheol2D ZAukG$r/]7GiMLvډ0`mާ3N?s47ȷ@a lOp.K569\dq>gq676g5lI~IEr) GzonxJ-u`o.-2%vy)3ȾfnMm9zMAJm)6W'`gv>;cuʲúh;k۾ʲ(*ڮ/k<^i6Y#d={=4RӱzĪAڏFk`Nwe[؇t9yKKp=G j)Eߣp"vxn3ƔӇfiPEkTj5&MYL* 2 f3G)3!ۚt) \)Tx/ϢCx'xKr,z؅.wvUt@§+}+] ~ qhO~@:_-/%6r|]XKہXK%VI\OK/au.NyXA>."L܁+>Sҙ@#1;1ɠ<H}D^\Gm|@W q& AnĮ(_-rnMvP!wme}]i`_d|d_O]p>YgbGo}A׏U}rH zObOc}Q_\FQEcNg^i_X( 6 d d<Clip (MS_ClipArt_Gallery.20,Microsoft Clip Gallery0>Clip (MS_ClipArt_Gallery.20,Microsoft Clip Galleryb/ 0DTimes New Roman$1bbv 0b( 0DSymbolew Roman$1bbv 0b( 0 ` .  @n?" dd@  @@`` 8? !%%  % 6     ?$2$X75;ky D=ƼT2${ĠЧx Tc $ ffff3@g4!d!dv 0bppp@  <4BdBd4b 0bbuʚ;2Nʚ;<4!d!d4b{ 0 bb<4dddd4b{ 0 bb:2___PPT9/ 0? % !"-*+."Ranbaxy Laboratories Limited  A responsible international player Cost effective drug development but at the same time a lot of R&D work Cost competitive quality manufacturing2#n /!Ranbaxy Laboratories Limited   Non infringing patent and regulatory framework In order to comply with patent and regulatory constraints not only in API but also in BIO-EQUIVALENT generic products Cost implications <( 0$Ranbaxy Laboratories Limited  RCost differential at production plant Not GMP: 50 GMP: 100 EU: 200 USA: 300 J&+RS 2&Ranbaxy Laboratories Limited   Supports the need to supply inexpensive and quality products to poorer countries But there must be an equal opportunity to recover cost in other marketsJSH.g 3'Ranbaxy Laboratories Limited  ,Cost recovery in advanced markets is more and more difficult Pressure from the Authorities to get the drug bill down Competition/purchasing groups Big Pharma tightening product patents Big Pharma post patent strategy stronger (in EU the  Is/Has Been Marketed interpretation) R>ZVZZZF    Q 4(Ranbaxy Laboratories Limited  NAnti-Aids drugs in Africa: $1 per day per patient Medium to long term there is a risk that poorer countries will not get access to modern medicines Neglected diseases will remain neglected, no incentive for R&D Comparitive pricing with more advanced market Old products will disappear PI, etc& :3ZZ'*   H 7*x  ` ̙33` ` ff3333f` 333MMM` f` f` 3>?" dd@,|?" dd@   " @ ` n?" dd@   @@``PR    @ ` ` p>>    6 (    6 j P  T Click to edit Master title style! !  0l   RClick to edit Master text styles Second level Third level Fourth level Fifth level!     S  0r ``  X*  0Dw `   Z*  0{ `   Z*zF     h :  s *A28 ??6-  $00_____   s *A28 ??G s  $0@_T  <v޽h @ ? ̙33 Default Design0 (    0 P    T*    0@     V*    6? `P   T*    6H `   V*  H  0޽h ? ̙33 SK0(    < ?Ranbaxy Laboratories Limited Differential Pricing & Financing of Essential Drugs Experience with Generic drugs Cecile H Miles Head of Western Europe Divisionh$ R$$/ H  0޽h ? ̙33 @l@( w l l T0gֳgֳ ?0 ,$0 HRanbaxy Today...$ l N2gֳgֳ?`,$0 N India s largest pharmaceutical company - amongst top 100 in the world, and 9th generic player in the world Global turnover for 2000 $ 505 million Branded pharmaceuticals, generics and APIs 5% market share in India about 12 % of country s pharmaceutical exports l  '  + K  LF+J  H l 0޽h ? ̙33E Pp(  pF p N=gֳgֳ?@,$0  Products sold in over 40 countries; manufacturing operations in 6 countries including India Employs about 7000 people, 17% of non Indian origin Expanding portfolio of international subsidiaries, joint ventures, affiliates and alliancesv \  4  \  ($$ p NQgֳgֳ?` ,$0 E International  p T0gֳgֳ ?0 ,$0 HRanbaxy Today...$H p 0޽h ? ̙33 C;`(    Tcgֳgֳ? p,$0 fKey Global markets $HH  %  <l`  SAmericas USA Brazil Europe UK Germany Western Europe Central Europe Eastern EuropeJT 9H  <`r`p S vAsia - Pacific India Vietnam China Malaysia Thailand Australia Myanmar New Zealand Africa South Africa Egypt NigeriaJwGH  0޽h ? ̙33 VNp(    N|gֳgֳ?P` ,$0 tR&D investment - 18% of Indian Pharmaceutical industry (annually) Increasing focus on discovery of new moleculesFE  / u8  Ngֳgֳ?P%,$0 NResearch & Development   Tgֳgֳ ?0 ,$0 HRanbaxy Today...$H  0޽h ? ̙33 JB( T%7 "  Tgֳgֳ? p,$0 jResearch & Development $HH  x  <d0 c bRanbaxy s advantage Low cost, high quality Highly qualified manpower at very low cost Innovative approach Areas of focus Chemical research Drug delivery New moleculeslZ2\3nCH  0޽h ? ̙33  $(  r  S (RP   r  S R  H  0޽h ? ̙33  D<(  r  S WP   r  S W    6Z g" B H  0޽h ? ̙33  $(  r  S `P   r  S a  H  0޽h ? ̙33  $(  r  S @iP   r  S i  H  0޽h ? ̙33  $(  r  S `{P   r  S |  H  0޽h ? ̙33  $(  r  S tP   r  S ~  H  0޽h ? ̙33 UM (    <Qa Ranbaxy Laboratories Limited The mission: To become a research based international pharmaceutical company The goal $ 1 billion by 2004 Cecile H Miles Head of Western Europe Division$ $B*$$/ $Lf  S @P   +  H  0޽h ? ̙330xY tUEҮ~// IX"YHX%A6Y%-,#3HALXp meDMT6 "@[}}/a.KuWwWWUWWwvz7_}I#x DM)aˍӀEU <A@0*=!@M@e ׬_4(hLu*WS"7Ӝty*MoX~%9 ϠԗR뚛s\s:!/u`tJdXFV_ٿpr(+Z6u~u<6KzX=l=0KuGqpZVO>GwwCዀ4z]j,\^Mr%5POsM,Ǩ>걨7Uz/]Mns۫o*j?Rp|vvX \`sT!?g:`9S%2/Ty1\ {joۡͻCW"P'AϪl;rG2W t(Gubp\AՄ?UyjʛԭIՂg~PEs U5*SM|ăUyaw0UA[s7D"nqh4E''7L&*r \@ʊߑbOS3+^VՇwmZa<~w:U\@giAlQ'_Կڑ R.邱5%ϧ6:7 'cʫ錱~0Ac Swy1vsh12o)011͡t5O!Nxy/B W)/O(\S#LM8Zrvc& jQgN$vS_^Lx dƃh' N܂q (Z4xBc9 +`'cg3<Hj芾\:r,B]dХ t EQГ%K";ayß ~-> ?%/Ic+x('>%i@*~p{x pQFD2qL&@K0C@ _?i 2Ys曄=8 mCZY BԬ/Cd,CPr- xh~giD4= yY>!A}%wc}>و vid{2Γýp8f, lNY^;hΦc wI͖~Q;G+9sK.4Զ12aɱȖqȌō)@}nF 95mxMp 4q!{א;vDI@7TO5/Z@wv?H&Xm?F@  -<ߣ*أ\xC^rz^5῎2e~h7vW Q],Q!(?xx,VDRzzo^$yZ{)I>ݡʪur9;ڣN9=\7ׁM7:ͳn-|]Ds)M( 'i0{V[~_R &j|yC,j9(O(NWlJs2euU2?}DfwwY#Ec%b̋T*$z_bTuDe@Qz0@C)wB$wDuADvAdvB&&Q{;Kw"F4Vקu4ҵnQ@5O8 Fk_/WGi:xSu=C* ivc:vR(= Y/ te쨊@0>KwvRY YA&mDݤkS!tΟ[8 s"VhP츚f"E^-Vur%<ZQasT5P BFAqEP>)>-'>!'OrD[{9z82>C̭h'z\(d$ty_}}e(O(IJW%Z~|ϛb>wq? ;pܪkaxrxV; ޅ}8FsCp[#$o3#H=~ѿd{Cfo s&=oxo;m[˭qlkHis9nw-dkn` AN'nN- no-nntd'!{N7Q[_Ө_₟"!]= 4E@pq.QR^g}'IET93Sl^,tR[/@8PK/B}1n܄r>c$oCD?1f_cAtz͈(} sGE<6m>oJ1 m{3ƿ 6Wl!g'D_,zD{3[@hoy- %=j9[a3h?HhCYB:h QE]D>rH]zCuj#'F>Fk9Vߊv@['S$2 Q ?*h *`d6Urx3{t5ri-nHUuE`TM쨍oF=hGSlUYG+!@04$'%w~} 'gur4#Oi2Y1Vگ6Qa=5UHOޛ,y bz|w{:m3"f#v Wb-+gQ~Joǀ:׀͗z sؓϡ/U2_<[!KzrJY*lkmȳt(MD!>Qth}dEo$[J;AKr=y *][?ןW{ R_?S_G/_7ߍ]( xW XUU^pA^a*Q*䣒b1t0i0 E>2ͨ|X**fD3Kf3^f>Ϲډho}Yk^{}{ͱe֓FO=`D5QJyjUK@f?o&/@ Wt(b( I, V-t@0Zqֽs0%RO4Gm`Ti^E5̛J'S&nBHF 4u%`R(ƶa>{ywg/˯ƜNYzWۯ 좗;w<ggzfȬԔά{RSHCFX?>wqv Q;-̰.aӲi Y)i ->Ι>ʙ06_Jjrf!LwɌ7'8sI YcG::bDzZ5⭂m&6$u ]"xS1XDI% 7=ܵv#6c=g_Xֳ8@U *1?e^Jyz`G}'Uٰ !lOLEjmM:(.zyKOI MwIugpCXwWgkB^üГX_'*(f,QouAUUUo!U}O2=#whEۚLWf]wwQ/js5^[Y+G<^HKЋh_mOhCK2I &P=Do qdc,b0ʏ䓻ܘ%{F2JgyD7P;u1^ů.Ƴ&u&nTDvn'z NkFNJg, qh\kvs>Kd&v֮3__GʯM2z\)R>A7yb$WSBr/-?S 0`0C"='C\N̑E]Ⱦb|H,E#VșT.)< MS2I|*'A ]dKљB)\NDN|_T:$>7ʑJfSL2 >&32&!(c)^0sjkF)Jq`q.E#:1؟vqWw;=c_l{f%6b-G[.Q ,yG9̀ Lb2H(.1¹@E*? < 0v( y6%V_ BQfHTbTl׊w\2O.Gx8I+4%g ~q>r؏xzG0Č?sTXn!m@Ds2VM+Mh8Dԃ/Qoh?!o!E[$pgmD+^M{k샽57t7!*m.MoގW !kofZ Z5CoBBi"O9`rK/sp*P*ki=`i8>I) ) }jqeK+xer)bƫ@ G{A{MJ[̱F25JfaTWkخ_2L`ˣj 0IW ച,.@tJ9q{̖5jԁSj&FBe>Z\* 9 {+jw~KC(jqhAqKr i~G 7Q(hq;W,Pf^ :A}b5RVy}ڭ?I*aU7RxJ*'~J,Tx b8oRyUz?Rm`A[R|Tmx^ȇaoT>fX|=b{[(#ݐ(!'ߓ;OGh4BŨe/QgЮ\NQ$3y5z}/T TKZ4UFS4A_GqϦSRϥa\U/(}5_#/({ywr0NN_~^xg¸;12]鼌 @+k锉 d'ў0ٖHN{w؏\D.UȒJymEBzPs ܄ 2p wRMBy4 2y7-B6 Γ4 ]/I=<{#Nh; iu͗UӪX~V+9@Q֠&&TKjdzJgNyRmT#{JS{+o@w*dX*?N) f Byw.T`޵\Nu3YNT6oR*Nn灾Z%ؤ蕪Co/G]~_XOwߎ}O,Z^߱l|}W BO!vg_{W {AEb}~j/fڮ6_3EZr`PuSpg'! P*X0* @:>-@5C|EH20JKM6 m#O r7 Oh+'0TN `h  No Slide Title Alind SharmaeCarl Sorensen44lMicrosoft PowerPointP@ɞ2@@h3O~@@5GBMg  && &&#TNPP2OMi & TNPP &&TNPP    && "--v- $ w- $   $x- $((y- $((22z- $22<<|- $<<FF}- $FFPP~- $PPZZ- $ZZdd- $ddnn- $nnxx- $xx- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $""- $"",,- $,,66- $66@@- $@@JJ- $JJTT- $TT^^- $^^hh- $hhrr- $rr||- $||- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $&&- $&&00- $00::- $::DD- $DDNN- $NNXX- $XXbb- $bbll- $llvv $vv- $- $ $- $ $- $ $- $- "--&&&G& - &Gy& &0P&/lQ.  --=; iʍ QB QB&PF & &$TNPPMicrosoft PowerPoint & TNPPf & &TNPP TN&RF "-- MFR & TNPP2.  - "- &kF & &$TNPPMicrosoft PowerPoint & TNPPP & &TNPP&mF-- FR & TNPP.  - "- &PJ & &$TPPMicrosoft PowerPoint & TPPL & &TNPP&PI-- FR & TPP.  - "-&MrEdMicrosoft Draw&MrEda Helvimmediately. &Other...-=[??__?_?_?_??___?߿?__?߿_?_ߟ߿____?___??_???___&MrEdZ   &Z &MrEdb X- "-DP& _&._&,_- & MrEd $".111467:;?CMSVX\^^ejp u w ~ $'-12/-//1555;=@ELRW]dipy~uuyxke_YWYTYTPTKC 977./31014.z(t$q#lmnkhb`Y S R O MGDA:61-*'!   & MrEd$S!K'P*[*d*[%S! & &.T & MrEd%NVVVRPN&.T & MrEdz$ |y~ #%|*}/y5t:r8m=gBbF_O`NYWT_QfPcWkOgKgA_Aa;x<4/})} ywupge\PPMHED%@-;%?=8./;DKOX[c_^WQXXQK57-,24p,g#fc\h h _bctrepy $+7=JZbpu]LFNTZep{  & MrEd"$"'+" & MrEd$ *1:AA<81* & MrEd"$>DFOOLLIIGC@9=> & MrEd$ PXZ^\YXVP & MrEd$ =EKFEBB?@= & MrEdr$7mgeb__ceggkkmsrrtvwxyywvx{{{unollgeggeb^^^_cbdfjlmlm & MrEd.$ow|}}}{yso & MrEd$$ & MrEd$@  & MrEd*$wILLNOKIFDF@<;:=?~C{GwI &  & & X- & MrEd\$,/-.- ,$.%.'2)3(5)9);-?/A0A1D.F)L(L'I(D)B(@"AFGKKIFDDA== >"<$;%:9444/ & MrEd$$S+U0Q+P(Q$S & MrEd$4Q:R?NB@ &  & &- - & MrEd$q4`FZNLVIb@nOuIyKHHID<33((&(,-25;FLKNS/F.>45;3>>?L\h$Sdv |j^WQH=3.*" }tmcYK:+$$##*//*{*t.p4`&$  eX- & MrEd$  & MrEd$*#$%..* & - & MrEd$SI#S Y#](b/a5Y=SAO@I>D>>C;C5A2D/I/J,J(L%X&\*p'q#k]VTTV\dinsz ~   !%%#%+*/2557<FLD=#4%'&$%%##  {laXND8~.p'b P7~{vrjbYR QKE??DE7, -543.$')'2$:$@-?,I%MS&Z.R3R:P@MEMKGQ?W=\;d9g;l:p8y8|9:83433:ABDFGJSWVX\\]UV\da_Z \c a cdffkm m s {|'&$!   $)-22-)(#!$'*-015248745:=:78641.)&%"!###&))&' %&%!#!'#,(--0/5-7'>!AI&DL & MrEd$   & MrEd2$ "!###   & MrEd $Q,S6Z7Q, & MrEd$h5n.s0o7h5 & MrEd $&*& & MrEd$ }}uv & X- & MrEdH$" &  &  & --''' & TPP-- ' & &TNPP & -- ' & TNPP-- ' & &TNPP & -- '   ' & TNPP-- ' & &TNPP & -- --'&&kO.  -->;  Q` Q`&rF & &$TNPPMicrosoft PowerPoint & TNPPf & &TNPP TZ&sH "- -  FHs & TNPP1.  - "- &uU & &$TNPPMicrosoft PowerPoint & TNPPP & &TNPP&sU- - Hs & TNPP.  - "-&VP & &$TPPMicrosoft PowerPoint & TPPL & &TNPP&UO- -Gs & TPP.  - "-&MrEdMicrosoft DrawZ&MrEdd Helvv@Z"Eurostile E&MrEd}   &} &MrEd$ X- "-Eq&~s- & MrEd$AHbCr>w5|1**($.9DJZq'0DVevxnhd\V>)#$|nlmnfuidbP|SbH\QRZHb & MrEd$ "a!v  &-z1p.k"a & MrEd$I3:;>EHIG?45288?@A>GIGJM~TwVnXg]ehgviwixg|lllu|ule`\XTMC;23 & MrEd$ /  & MrEd$]K<A`g] & MrEd$(-)1  & MrEd$.)?@2B5.) & MrEd$  & MrEd*$%5C|OyaaQOD.&  & MrEd$gkebdg & MrEd$ quqqyxsnlnlq & MrEd${x}~{ & MrEd $qqoq & MrEd$ & MrEd($}{{~~|xxr & MrEd$ xupjjswvyx & MrEd$ ( 7<ELTd ]J? ( & MrEd$16411 & MrEd$8=CC8 & MrEd $JJQJ & MrEd$Bfx]XdTX$]:tFl~u}|#u+p1x:{?wJrNqFp>7?^j{<)35$){gqS3w ,5tpmd]IPPH??;;33.$$""#$(# $03;;==CIQLIB<4)%%+7AB@BEJC91-),,oDbDZ<Z/^)^kr'xxr  +'B &  & - -''' & TPP- -' & &TNPP & - -' & TNPP- - ' & &TNPP & - - ' ' & TNPP- -  ' & &TNPP & - -  --'&&--'}-- @Times New Roman-  .2 Ranbaxy # . .%2 cLaboratories Limited   ) . "----   .%2 Differential Pricing#   . . 2 W&(. .12 Financing of Essential Drugs      #. .32 Experience with Generic drugs   "  & .@Times New Roman-   .2 Cecile H Miles  . .62 kHead of Western Europe Division    .--"System- &TNPP & ՜.+,0`    On-screen ShowRanbaxyw  Times New RomanSymbolDefault DesignMicrosoft Clip GalleryPowerPoint PresentationPowerPoint PresentationPowerPoint PresentationPowerPoint PresentationPowerPoint PresentationPowerPoint PresentationRanbaxy Laboratories LimitedRanbaxy Laboratories LimitedRanbaxy Laboratories LimitedRanbaxy Laboratories LimitedRanbaxy Laboratories LimitedRanbaxy Laboratories Limited  Fonts UsedDesign TemplateEmbedded OLE Servers Slide Titles %_s Carl SorensenCarl Sorensen  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnoqrstuvwyz{|}~Root EntrydO)PicturesCurrent UserxSummaryInformation(HNPowerPoint Document(,sDocumentSummaryInformation8p